Prestige to buy Insight Pharma for about $750M

The Tarrytown, N.Y., company said Friday that the deal for the privately held company will expand its over-the-counter product portfolio to include products like the yeast infection treatment Monistat and other feminine care products.

Prestige also is acquiring tax attributes of about $100 million, which would lower the purchase price to $650 million.

Prestige Brands Holdings Inc. will use cash, its revolving credit agreement and an add-on it to its existing term loan to pay for the deal.